LeonaBio's 23M Series A Warrants Now Exercisable, Potential $146.2M Cash Inflow
LONA sits 68% above its 52-week low of $3.6.
Summary
LeonaBio's 23M Series A warrants are now exercisable, potentially bringing in $146.2M in cash if fully exercised. The exercise window runs through October 19, 2026.
Key Events · Financing and Capital Events · LONA
-
Series A Warrants Exercisable
23,031,494 Series A Common Warrants became exercisable on September 18, 2026, and remain exercisable until October 19, 2026.
-
Potential $146.2M Cash Inflow
If exercised in full for cash at $6.35 per share, the warrants would provide approximately $146.2 million of additional capital.
-
Exercise Price Above Market
The $6.35 exercise price is above the current stock price of $6.05, which may lead holders to choose cashless exercise or let warrants expire.
-
Going Concern Context
The company's last 10-Q disclosed a going concern warning with $51.1M in cash that may not last 12 months, making this potential capital infusion critical.
Analysis · LONA · Life Sciences
The Series A Common Warrants became exercisable on September 18, 2026, and remain exercisable until October 19, 2026. If exercised in full for cash, they would provide approximately $146.2 million of additional capital. This is a significant potential financing event for a company with a going concern warning and only $51.1 million in cash as of its last 10-Q. The exercise price of $6.35 per share is above the current stock price of $6.05, which may influence whether holders choose to exercise for cash or on a cashless basis.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $6.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57M. The 52-week trading range was $3.60 to $14.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.